 SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 GLOBE NEWSWIRE -- DICE Therapeutics, Inc. Nasdaq: DICE, a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the following investor conferences: 